Cerebrolysin Research for Vascular Dementia
An evidence-based overview of research examining Cerebrolysin in the context of vascular dementia. This page synthesizes findings from peer-reviewed literature.
Research Summary
Cerebrolysin has shown benefit in vascular dementia trials. A study of 242 patients demonstrated significant improvement in ADAS-cog+ and CGI scores, with notable executive function domain benefit. The neuroprotective and neuroplasticity-promoting effects may be particularly relevant for vascular cognitive impairment.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Vascular Dementia
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Cerebrolysin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.